Download MendeleyDiscovery of Non-Nucleotide Small-Molecule STING Agonists via Chemotype Hybridization.
Cherney, E.C., Zhang, L., Lo, J., Huynh, T., Wei, D., Ahuja, V., Quesnelle, C., Schieven, G.L., Futran, A., Locke, G.A., Lin, Z., Monereau, L., Chaudhry, C., Blum, J., Li, S., Fereshteh, M., Li-Wang, B., Gangwar, S., Pan, C., Chong, C., Zhu, X., Posy, S.L., Sack, J.S., Zhang, P., Ruzanov, M., Harner, M., Akhtar, F., Schroeder, G.M., Vite, G., Fink, B.(2022) J Med Chem 65: 3518-3538
- PubMed: 35108011 Search on PubMed
- DOI: https://doi.org/10.1021/acs.jmedchem.1c01986
- Primary Citation Related Structures:
7SSM - PubMed Abstract:
The identification of agonists of the stimulator of interferon genes (STING) pathway has been an area of intense research due to their potential to enhance innate immune response and tumor immunogenicity in the context of immuno-oncology therapy. Initial efforts to identify STING agonists focused on the modification of 2',3'-cGAMP ( 1 ) (an endogenous STING activator ligand) and other closely related cyclic dinucleotides (CDNs). While these efforts have successfully identified novel CDNs that have progressed into the clinic, their utility is currently limited to patients with solid tumors that STING agonists can be delivered to intratumorally. Herein, we report the discovery of a unique class of non-nucleotide small-molecule STING agonists that demonstrate antitumor activity when dosed intratumorally in a syngeneic mouse model.
- Bristol Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States.
Organizational Affiliation:
